Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13125415 | 0.85 | KMT2A (0.33) | KMT2AATMMGLL | |
| SCHEMBL12048292 | 0.80 | CA1 (0.35) | KMT2AATMLMNACA12CA1 | |
| SCHEMBL1480734 | 0.79 | ALDH1A1 (0.34) | KMT2AATMLMNACA12CA1 | |
| SCHEMBL16133577 | 0.79 | MGLL (0.35) | KMT2AATMLMNACA12CA1 | |
| SCHEMBL261924 | 0.79 | MGLL (0.35) | KMT2AATMLMNACA12CA1 | |
| SCHEMBL13160466 | 0.78 | MGLL (0.34) | KMT2AATMMGLL | |
| SCHEMBL15725705 | 0.77 | — | — | |
| SCHEMBL277826 | 0.77 | MGLL (0.33) | KMT2AATMMGLL | |
| SCHEMBL13284813 | 0.76 | KMT2A (0.30) | KMT2AATM | |
| SCHEMBL11955614 | 0.76 | MAPT (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293869-B2 | Polymer conjugates of GLP-1 | NEKTAR THERAPEUTICS (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120244597-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245289-A1 | POLYMER-FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2012-09-27 | — | — | US | disclosed |
| US-8273339-B2 | Polymer-based compositions and conjugates of antimicrobial agents | NEKTAR THERAPEUTICS (US) | 2012-09-25 | — | — | US | disclosed |
| US-8247536-B2 | Factor VIII compositions | NEKTAR THERAPEUTICS (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120195847-A1 | POLYMER CONJUGATES OF BIPHALIN PEPTIDES | NEKTAR THERAPEUTICS (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120178692-A1 | DOSAGE FORMS OF POLYMER-FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120100096-A1 | CONJUGATES PF SMALL-INTERFERING NUCLEIC ACIDS | NEKTAR THERAPEUTICS (US) | 2012-04-26 | — | — | US | disclosed |
| US-8143378-B2 | Polymer factor VIII moiety conjugates | NEKTAR THERAPEUTICS (US) | 2012-03-27 | — | — | US | disclosed |
| US-8133977-B2 | Polymer-factor VIII moiety conjugates | NEKTAR THERAPEUTICS (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100130428-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130684-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100125049-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120689-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS (US) | 2010-01-28 | — | — | US | disclosed |
| US-20090280550-A1 | Polymer-Factor IX Moiety Conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-7579444-B2 | Polymer-factor IX moiety conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-02-12 | — | — | US | disclosed |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | F13B, F8, F13A1 | KMT2A 1613/4885ATM 4202/4885LMNA 2605/4885 |
| US-20100120689-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | KMT2A 1159/4885ATM 2304/4885LMNA 700/4885 |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | F9, F13A1, F13B | KMT2A 2142/4885ATM 3043/4885LMNA 1157/4885 |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | KMT2A 4160/4885ATM 3261/4885LMNA 2141/4885 |
| US-20100125049-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | KMT2A 1159/4885ATM 2304/4885LMNA 700/4885 |
| US-20100130684-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | KMT2A 2002/4885ATM 2961/4885LMNA 860/4885 |
| US-20120178692-A1 | DOSAGE FORMS OF POLYMER-FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | KMT2A 1404/4885ATM 2822/4885LMNA 965/4885 |
| US-20120245289-A1 | POLYMER-FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | KMT2A 1225/4885ATM 2415/4885LMNA 811/4885 |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | F8, F13A1, F13B | KMT2A 1218/4885ATM 3546/4885LMNA 1408/4885 |
| US-20120195847-A1 | POLYMER CONJUGATES OF BIPHALIN PEPTIDES | NGLY1, DNPEP, CIAPIN1 | KMT2A 3443/4885ATM 4877/4885LMNA 4562/4885 |
| US-20100130428-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | KMT2A 2002/4885ATM 2961/4885LMNA 860/4885 |
| US-20120100096-A1 | CONJUGATES PF SMALL-INTERFERING NUCLEIC ACIDS | SLC19A1, FOLR1, SLC46A1 | KMT2A 867/4885ATM 3807/4885LMNA 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.